Abstract
Prognosis of second‐relapsed/refractory first‐relapsed childhood acute myeloid leukaemia remains poor and there are no clear guidelines on the best treatment approach. The report by White et al. suggests that, while outcomes are still unsatisfactory, there is room to pursue a curative approach rather than palliation.Commentary on: White et al. Clinical outcomes of second relapsed and refractory first relapsed paediatric AML: A retrospective study within the NOPHO‐DB SHIP consortium. Br J Haematol 2022;197:755‐765.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
